<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="73993">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02068443</url>
  </required_header>
  <id_info>
    <org_study_id>SYR-322-MET/CCT-001</org_study_id>
    <secondary_id>JapicCTI-132377</secondary_id>
    <secondary_id>U1111-1151-6515</secondary_id>
    <nct_id>NCT02068443</nct_id>
  </id_info>
  <brief_title>Double-blind Comparative Study of SYR-322-MET.</brief_title>
  <official_title>Double-blind Comparative Study When Metformin Hydrochloride is Added on to SYR-322.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of treatment with metformin hydrochloride in diabetic
      patients when used in combination with SYR-322.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>HbA1c</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measurement of change from baseline in HbA1c</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HbA1c and fasting blood glucose</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measurement of HbA1c and fasting blood glucose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of cases with adverse events</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">385</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>QD combination group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BID combination group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SYR-322 alone group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SYR-322 + metformin hydrochloride</intervention_name>
    <arm_group_label>QD combination group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SYR-322 + metformin hydrochloride</intervention_name>
    <arm_group_label>BID combination group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SYR-322 + metformin hydrochloride placebo</intervention_name>
    <arm_group_label>SYR-322 alone group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient who is an outpatient during the observation period.

          -  Patient who signs and dates a written, informed consent form and any required privacy
             authorization prior to the initiation of any study procedures.

        Exclusion Criteria:

          -  Patient who has any serious cardiac disease, serious cerebrovascular disorder, or any
             serious pancreatic or hematological disease.ï¼ˆe.g., subjects who require
             hospitalization or subjects who were hospitalized within 24 weeks prior to the
             commencement of the observation period)

          -  Patient who is considered ineligible for the study for any other reason by the
             investigator or subinvestigator.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Months</minimum_age>
    <maximum_age>74 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Takeda Study Registration Call Center</last_name>
    <phone>+1-800-778-2860</phone>
    <email>medicalinformation@tpna.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Sendai-shi</city>
        <state>Miyagi</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 19, 2014</lastchanged_date>
  <firstreceived_date>February 19, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alogliptin</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
